Capstone Financial Advisors Inc. Acquires New Position in NeoGenomics, Inc. $NEO

Capstone Financial Advisors Inc. bought a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 2nd quarter, Holdings Channel reports. The firm bought 10,000 shares of the medical research company’s stock, valued at approximately $73,000.

A number of other hedge funds also recently added to or reduced their stakes in NEO. First Light Asset Management LLC lifted its position in shares of NeoGenomics by 90.8% during the 1st quarter. First Light Asset Management LLC now owns 6,042,822 shares of the medical research company’s stock valued at $57,346,000 after acquiring an additional 2,875,237 shares during the period. American Century Companies Inc. increased its stake in NeoGenomics by 14.7% in the 1st quarter. American Century Companies Inc. now owns 3,319,602 shares of the medical research company’s stock valued at $31,503,000 after purchasing an additional 426,341 shares in the last quarter. Geode Capital Management LLC increased its stake in NeoGenomics by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 3,156,621 shares of the medical research company’s stock valued at $23,078,000 after purchasing an additional 26,224 shares in the last quarter. Jennison Associates LLC raised its holdings in NeoGenomics by 8.9% during the second quarter. Jennison Associates LLC now owns 1,663,905 shares of the medical research company’s stock worth $12,163,000 after purchasing an additional 136,638 shares during the last quarter. Finally, Royce & Associates LP boosted its position in NeoGenomics by 27.0% during the first quarter. Royce & Associates LP now owns 858,046 shares of the medical research company’s stock worth $8,143,000 after purchasing an additional 182,180 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Trading Up 0.1%

Shares of NEO stock opened at $10.01 on Friday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -11.38 and a beta of 1.67. The company has a current ratio of 3.91, a quick ratio of 3.58 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $9.19 and a 200 day moving average price of $7.82. NeoGenomics, Inc. has a twelve month low of $4.72 and a twelve month high of $19.11.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01. The company had revenue of $187.80 million for the quarter, compared to analysts’ expectations of $183.85 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period last year, the company earned $0.05 EPS. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Research analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

NEO has been the subject of a number of research analyst reports. BTIG Research restated a “neutral” rating on shares of NeoGenomics in a research report on Wednesday, July 30th. Piper Sandler set a $11.00 price objective on shares of NeoGenomics and gave the company an “overweight” rating in a research note on Monday, August 4th. Needham & Company LLC raised their target price on shares of NeoGenomics from $8.00 to $14.00 and gave the company a “buy” rating in a report on Friday, August 29th. Stephens lifted their target price on shares of NeoGenomics from $6.50 to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 2nd. Finally, William Blair reiterated a “market perform” rating on shares of NeoGenomics in a research report on Tuesday, July 29th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $13.11.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.